Influenza Activity - United States, 2015-16 Season and Composition of the 2016-17 Influenza Vaccine.
During the 2015-16 influenza season (October 4, 2015-May 21, 2016) in the United States, influenza activity* was lower and peaked later compared with the previous three seasons (2012-13, 2013-14, and 2014-15). Activity remained low from October 2015 until late December 2015 and peaked in mid-March 2016. During the most recent 18 influenza seasons (including this season), only two other seasons have peaked in March (2011-12 and 2005-06). Overall influenza activity was moderate this season, with a lower percentage of outpatient visits for influenza-like illness (ILI),(†) lower hospitalization rates, and a lower percentage of deaths attributed to pneumonia and influenza (P&I) compared with the preceding three seasons. Influenza A(H1N1)pdm09 viruses predominated overall, but influenza A(H3N2) viruses were more commonly identified from October to early December, and influenza B viruses were more commonly identified from mid-April through mid-May. The majority of viruses characterized this season were antigenically similar to the reference viruses representing the recommended components of the 2015-16 Northern Hemisphere influenza vaccine (1). This report summarizes influenza activity in the United States during the 2015-16 influenza season (October 4, 2015-May 21, 2016)(§) and reports the vaccine virus components recommended for the 2016-17 Northern Hemisphere influenza vaccines.
Stacy L
SL
Davlin
Lenee
L
Blanton
Krista
K
Kniss
Desiree
D
Mustaquim
Sophie
S
Smith
Natalie
N
Kramer
Jessica
J
Cohen
Charisse Nitura
CN
Cummings
Shikha
S
Garg
Brendan
B
Flannery
Alicia M
AM
Fry
Lisa A
LA
Grohskopf
Joseph
J
Bresee
Teresa
T
Wallis
Wendy
W
Sessions
Rebecca
R
Garten
Xiyan
X
Xu
Anwar Isa Abd
AI
Elal
Larisa
L
Gubareva
John
J
Barnes
David E
DE
Wentworth
Erin
E
Burns
Jacqueline
J
Katz
Daniel
D
Jernigan
Lynnette
L
Brammer
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D046688:Child Mortality; D002675:Child, Preschool; D024882:Drug Resistance, Viral; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D007223:Infant; D007226:Infant Mortality; D007231:Infant, Newborn; D053118:Influenza A Virus, H1N1 Subtype / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification*; D053122:Influenza A Virus, H3N2 Subtype / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification*; D009981:Influenza B virus / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification*; D007252:Influenza Vaccines / Q000737:chemistry; D007251:Influenza, Human / Q000453:epidemiology* / Q000401:mortality / Q000517:prevention & control / Q000821:virology; D008875:Middle Aged; D010045:Outpatients / Q000706:statistics & numerical data; D011014:Pneumonia / Q000401:mortality; D011159:Population Surveillance; D012621:Seasons; D014481:United States / Q000453:epidemiology; D055815:Young Adult
D007252:Influenza Vaccines